Detailed explanation of scope of application and usage and dosage of Osimertinib

Osimertinib (Osimertinib), trade name Tagrisso/AZD9291/Tagrisso, is a highly efficient and selective EGFR mutant inhibitor, mainly used to treat patients with non-small cell lung cancer (NSCLC). As the world's first third-generation targeted therapy drug, osimertinib has shown excellent results in the treatment of EGFR mutant lung cancer, especially showing better activity against brain metastasis (CNS) lesions. It blocks the growth and spread of cancer cells by inhibiting EGFR mutants, thereby prolonging the survival of patients.

Osimertinib has a very broad scope of application, covering multiple NSCLC treatment scenarios. First, it is used as adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer, particularly those whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations. These patients can be treated with osimertinib to prevent tumor recurrence after an FDA-approved test confirms the presence of the relevant EGFR mutation. Second, osimertinib is also an effective treatment option for patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or after concurrent or sequential platinum-based chemoradiotherapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations. In addition, osimertinib can be used as a first-line treatment option for adult patients with metastatic NSCLC who have been detected with EGFR exon 19 deletion or exon 21 L858R mutation.

In terms of combination therapy, the combination of osimertinib, pemetrexed and platinum-based chemotherapy drugs provides a new first-line treatment option for patients with locally advanced or metastatic NSCLC. This combination therapy is particularly suitable for patients whose tumors harbor EGFR exon 19 deletions or exon 21 L858R mutations. Finally, osimertinib can also provide effective treatment for adult patients with detected metastatic EGFR T790M mutation-positive NSCLC whose disease has progressed during or after EGFR TKI treatment.

In terms of usage and dosage, the recommended dose of osimertinib is 80 mg once daily. Patients can take it with a meal or on an empty stomach, depending on personal habits and comfort. Medication may need to be suspended in patients who experience adverse events or toxicity. While taking osimertinib, patients should follow the doctor's instructions and undergo regular liver and kidney function and other related tests to ensure the safety and effectiveness of the drug.

In short, osimertinib has become an important drug in the treatment of non-small cell lung cancer due to its wide scope of application and clear efficacy. However, patients still need to pay attention to the side effects and interactions of drugs during use, and use them rationally under the guidance of a doctor. There are currently multiple versions of osimertinib on the market for patients to choose from, with different prices. Patients can make a choice based on their own circumstances, but they must ensure that they are purchased through legal and formal channels.